April 11, 2016 - The U.S. Food and Drug Administration (FDA) has approved the world's smallest pacemaker, the Medtronic Micra Transcatheter Pacing System (TPS). The device is the first FDA-approved product with miniaturized pacing technology that is cosmetically invisible and small enough to be delivered through a catheter. It is implanted directly into the heart, providing a safe alternative to conventional pacemakers without the complications associated with cardiac lead wires.

New data from an ongoing post-marketing study confirm the safety profile of Xarelto (rivaroxaban) was generally consistent with the findings observed in the ROCKET AF Phase 3 study that supported approval of the medicine for prevention of stroke in patients with non-valvular atrial fibrillation (NVAF).

Depression is a known risk factor for cardiovascular disease, but as a person’s depression improves — or grows worse — their risk for heart disease has remained largely unknown.

Toshiba America Medical Systems Inc. has received authorization to operate (ATO) with the U.S. Air Force for its Aplio Platinum Series ultrasound systems.

April 7, 2016 — Circle Cardiovascular Inc. the world-leading developer of innovative cardiac MR (CMR) and cardiac CT (CCT) post-processing software announces the completion of a substantial financing round with participation from existing investors including BDC Capital and new investors, The Accelerate Fund and Epic Capital Management Inc.

Emergency department patients with low-risk chest pain show improved knowledge of their health status and follow-up options after talking through treatment options with a physician, according to Mayo Clinic research.

PARTNER II, Sapien 3, TAVR superior to surgery, severe aortic stenosis, ACC 2016

April 7, 2016 — New data demonstrates that for aortic stenosis patients at intermediate-risk for open-heart surgery, transcatheter aortic valve replacement (TAVR) with the latest generation of balloon-expandable device is superior to surgery, resulting in better patient outcomes.

April 6, 2016 — Tests used to diagnose and assess the severity of coronary artery disease appear to function differently for women and men who have stable symptoms, according to researchers from Duke Clinical Research Institute.

The finding, presented April 4 at the American College of Cardiology (ACC) Scientific Sessions meeting in Chicago, adds new insights into the differences between men and women who are newly diagnosed with heart disease.

End-stage heart failure patients treated with stem cells harvested from their own bone marrow experienced 37 percent fewer cardiac events — including deaths and heart failure hospital admissions — than a placebo-controlled group, according to a new study.

North Fulton Hospital, Roswell, Ga., is one of the first healthcare providers in the United States to purchase the new Carestream Touch Prime XE Ultrasound System.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now